Literature DB >> 26295386

Genetic Polymorphisms of Glutathione-Related Enzymes (GSTM1, GSTT1, and GSTP1) and Schizophrenia Risk: A Meta-Analysis.

Su Kang Kim1, Sang Wook Kang2, Joo-Ho Chung3, Hae Jeong Park4, Kyu Bong Cho5, Min-Su Park6.   

Abstract

The association between polymorphisms of glutathione-related enzyme (GST) genes and the risk of schizophrenia has been investigated in many published studies. However, their results were inconclusive. Therefore, we performed a meta-analysis to explore the association between the GSTM1, GSTT1, and GSTP1 polymorphisms and the risk of schizophrenia. Twelve case-control studies were included in this meta-analysis. The odds ratio (OR) and 95% confidence interval (95% CI) were used to investigate the strength of the association. Our meta-analysis results revealed that GSTM1, GSTT1, and GSTP1 polymorphisms were not related to risk of schizophrenia (p > 0.05 in each model). Further analyses based on ethnicity, GSTM polymorphism showed weak association with schizophrenia in East Asian population (OR = 1.314, 95% CI = 1.025-1.684, p = 0.031). In conclusion, our meta-analysis indicated the GSTM1 polymorphism may be the only genetic risk factor for schizophrenia in East Asian population. However, more meta-analysis with a larger sample size were needed to provide more precise evidence.

Entities:  

Keywords:  glutathione S-transferase enzymes; meta-analysis; polymorphism; schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26295386      PMCID: PMC4581314          DOI: 10.3390/ijms160819602

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


1. Introduction

Schizophrenia is a mental disorder that is characterized by abnormal social behavior and altered perception of reality. Several studies suggested that genetic background and environmental factors play an important role in the development of schizophrenia. Recently, there has also been increasing interest in the role of free oxidative stress in the pathogenesis of schizophrenia. Oxidative damage and neuronal inflammation can lead to the onset of schizophrenia [1,2,3,4,5]. Glutathione S-transferases (GSTs) are a family of eukaryotic and prokaryotic phase II metabolic isozymes. GSTs are one of the key enzymes that regulate the conversion of toxic compounds to hydrophilic metabolites for the purpose of detoxification [6,7]. In addition, they play an important role as neuro-protective antioxidants by protecting neural cells from oxidative stress [4,8,9]. GSTs are expressed in many tissues in the human body. Some studies showed that GST levels of the cerebrospinal fluid were decreased in patients with schizophrenia [10]. It suggested that GSTs may play a significant role in the development and progression of schizophrenia. Human cytosolic GSTs belong to the alpha, zeta, theta, mu, pi, sigma, kappa, and omega classes and the main GSTs genes described as polymorphic in humans are glutathione S-transferase Mu1 (GSTM1), glutathione S-transferase T1 (GSTT1), and glutathione S-transferase P1 (GSTP1) [11,12,13,14]. The GSTM1 gene is located at 1p13.3, and the most common polymorphism in GSTM1 is a deletion of the whole GSTM1 gene with a lack of enzyme activity. The GSTT1 gene is located at 22q11.2, and a homozygous deletion in GSTT1 has also been reported. The GSTP1 gene is located at 11q13, and the functional polymorphism at codon 105 in exon 5 of GSTP1 has been found [11,12,13,14]. These polymorphisms of GSTM1, GSTT1, and GSTP1 have been investigated with various diseases including schizophrenia, hypertension, and capacity for oxidation and detoxification [15,16]. Previous studies showed that GSTM1 or GSTT1 deletion polymorphisms were contributed to the loss of GST enzyme activities, respectively. So, combination in these GSTM1 and GSTT1 polymorphisms have been also investigated in order to find relationship with various diseases. Up to now, a number of studies have evaluated the association between polymorphisms of GSTs gene and risk of schizophrenia in diverse populations. However, these results from the published studies remain conflicting rather than conclusive. Therefore, we performed a meta-analysis on all eligible case-control studies to clarify the association between the GSTM1, GSTT1, and GSTP1 polymorphisms and risk of schizophrenia.

2. Results and Discussion

2.1. Study Characteristics

The meta-analysis of this study was included 12 case and control studies. The characteristics from selected studies in GSTM1, GSTT1, and GSTP1 polymorphisms and schizophrenia are summarized in Table 1. The 12 articles included 2742 schizophrenia patients and 2762 control subjects. The number of analyzed articles for GSTM1, GSTT1, and GSTP1 polymorphisms were nine, eight, and four articles, respectively [3,17,18,19,20,21,22,23,24,25,26,27].
Table 1

Information of eligible studies included in the meta-analysis.

AuthorsPopulationSchizophrenia/ControlSchizophreniaControl
GSTM1 GSTT1 GSTP1 GSTM1 GSTT1 GSTP1
NullPresentNullPresentIle/IleIle/ValVal/ValNullPresentNullPresentIle/IleIle/ValVal/Val
Harada et al. (2001) [17]Japanese87/1765730NDNDNDNDND8789NDNDNDNDND
Pae et al. (2004) [18]Korean111/1307041NDNDNDNDND6169NDNDNDNDND
Matsuzawa et al. (2009) [19]Japanese214/220129858812715455511910180140162544
Rodríguez-Santiago et al. (2009) [20]Spanish594/585243351142452NDNDND289296105480NDNDND
Watanabe et al. (2010) [21]Japanese627/620336291NDNDNDNDND323297NDNDNDNDND
Gravina et al. (2011) [22]Italy138/1338256251136650870633010365489
Kashani et al. (2012) [23]Iran93/99157868748378267329764278
Kordi-Tamandani et al. (2014) [24]Iran80/71NDND1664NDNDNDNDND3437NDNDND
Pae et al. (2003) [3]Korean214/110NDNDNDND139687NDNDNDND74333
Raffa et al. (2013) [25]Tunisia138/12379595979NDNDND63606756NDNDND
Saadat et al. (2007) [26]Iran292/292NDND52240NDNDNDNDND99193NDNDND
Saruwatari et al. (2013) [27]Japanese154/20377776886NDNDND9910499104NDNDND
Total-2742/27621091106545612484072102811361153516121036516224

ND, no data; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1; GSTP1, glutathione S-transferase pi 1.

2.2. Quantitative Synthesis

The results of this heterogeneity test for meta-analysis are shown in Table 2. The random-effects method was applied if the result of the Q test was p < 0.05 or I2 statistic was >50%. Otherwise, the fixed-effects method was adopted. For GSTM1 polymorphism, nine studies containing 2156 schizophrenia patients and 2289 control subjects were included. GSMT1 polymorphism did not show any significant association with schizophrenia (null type vs. present type, OR = 1.140, 95% CI = 0.893–1.455, p = 0.294 in Table 2 and Figure 1A). For GSTT1 polymorphism, eight studies containing 1703 schizophrenia patients and 1726 control subjects were included. GSTT1 polymorphism did not show any significant association with schizophrenia (null type vs. present type, OR = 0.777, 95% CI = 0.510–1.185, p = 0.241 in Table 2 and Figure 1B). Combination of GSTM1 and GSTT1 polymorphisms were analyzed using meta-analysis. Combination of Null type in GSTM1 and GSTT1 polymorphisms were compared with combination of other types in GSTM1 and GSTT1 polymorphisms between the schizophrenia group and the control group. Combinations of GSTM1 and GSTT1 polymorphisms were not associated with schizophrenia (OR = 1.241, 95% CI = 0.866–1.777, p = 0.240 in Table 3).
Table 2

Overall analysis between polymorphisms of glutathione S-transferase genes (GSTM1, GSTT1, and GSTP1) and susceptibility of schizophrenia.

Gene SymbolsComparsionsPopulationHeterogeneityModelOR95% CI p
p I2
GSTM1 Null type vs. Present typeAll0.00170.969Random1.1400.893–1.4550.294
East Asian0.09050.291Random1.3141.025–1.6840.031
GSTT1 Null type vs. Present typeAll<0.00183.745Random0.7770.510–1.1850.241
East Asian0.19440.655Fixed1.0200.767–1.3550.893
GSTP1 Ile/Ile vs. Ile/ValAll0.4870.000Fixed1.1670.905–1.5040.235
Ile/Ile vs. Val/ValAll0.9390.000Fixed1.1440.640–2.0430.650
Ile/Ile vs. Ile/Val + Val/ValAll0.5330.000Fixed1.1630.911–1.4840.227
Ile/Ile + Ile/Val vs. Val/ValAll0.8890.000Fixed0.7710.435–1.3680.374
Ile vs. ValAll0.6660.000Fixed1.1210.912–1.3770.277
Ile/Ile vs. Ile/ValEast Asian0.9450.000Fixed1.0820.779–1.5040.637
Ile/Ile vs. Val/ValEast Asian0.9540.000Fixed1.2790.490–3.3390.615
Ile/Ile vs. Ile/Val + Val/ValEast Asian0.9540.000Fixed1.9070.797–1.5100.569
Ile/Ile + Ile/Val vs. Val/ValEast Asian0.9820.000Fixed0.9560.367–2.4900.927
Ile vs. ValEast Asian0.9790.000Fixed1.0950.827–1.4500.525

OR, odds ratio; CI, confidence interval; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1; GSTP1, glutathione S-transferase pi 1.

Figure 1

Odds ratio and 95% CIs are presented for individual studies (black square and line) and meta-analysis results (diamond). (A) Analysis of null type vs. present type of GSTM1 polymorphism; (B) Analysis of null type vs. present type of GSTT1 polymorphism; (C) Analysis of Val allele vs. Ile allele of GSTP1 polymorphism.

Table 3

Overall analysis between combination of glutathione S-transferase genes (GSTM1 and GSTT1) and susceptibility of schizophrenia.

Gene symbolsCombinationPopulationHeterogeneityModelOR95% CI p
p I2
GSTM1-GSTT1 Null type vs. other typesAll0.958<0.001Fixed1.2410.866–1.7770.240

OR, odds ratio; CI, confidence interval.

For GSTP1 polymorphism, four studies containing 659 schizophrenia patients and 562 control subjects were included. The genotype and allele of GSTP1 were also not found to be associated with schizophrenia (codominant, dominant, recessive, and allele models, p > 0.05, respectively in Table 2 and Figure 1C). When stratified for ethnicity of East Asian, GSTM1 polymorphism showed weak association with schizophrenia (OR = 1.314, 95% CI = 1.025–1.684, p = 0.031). However, there was no association between, GSTT1 or GSTP1 polymorphisms and schizophrenia (p > 0.05 in Table 2 and Table 3). To identify publication bias in meta-analysis, we evaluated publication bias using Egger’s regression. There was no publication bias (p > 0.05). Information of eligible studies included in the meta-analysis. ND, no data; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1; GSTP1, glutathione S-transferase pi 1. Overall analysis between polymorphisms of glutathione S-transferase genes (GSTM1, GSTT1, and GSTP1) and susceptibility of schizophrenia. OR, odds ratio; CI, confidence interval; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1; GSTP1, glutathione S-transferase pi 1. Overall analysis between combination of glutathione S-transferase genes (GSTM1 and GSTT1) and susceptibility of schizophrenia. OR, odds ratio; CI, confidence interval. Odds ratio and 95% CIs are presented for individual studies (black square and line) and meta-analysis results (diamond). (A) Analysis of null type vs. present type of GSTM1 polymorphism; (B) Analysis of null type vs. present type of GSTT1 polymorphism; (C) Analysis of Val allele vs. Ile allele of GSTP1 polymorphism.

2.3. Discussion

Oxidative stress-mediated neuronal damage has been regarded as an important factor in the development of schizophrenia. We supposed that GSTs play an important role in antioxidant defenses by modulating various kinases, and we hypothesized that GSTs are related to the development of schizophrenia. [28,29,30]. In the present study, we examined the association between the polymorphisms of GSTM1, GSTT1, and GSTP1 and the schizophrenia risk. To the best of our knowledge, this is the first meta-analysis to investigate the association between these polymorphisms and the development of schizophrenia. The correlations between GSTM1, GSTT1, and GSTP1 polymorphisms and the risk of schizophrenia have been investigated in a broad range of studies with either a relatively small or larger sample of the various populations. However, because of the differences in the number of participants and their genetic backgrounds, the evidence provided by each study is not sufficient to draw a convincing conclusion. We conducted a meta-analysis including with 2742 schizophrenia and 2762 controls from 12 case-control studies to evaluate the association between GSTM1, GSTT1, and GSTP1 polymorphisms and the development of schizophrenia. In our study, there were no significant associations between GSTM1, GSTT1, and GSTP1 polymorphisms and risk of schizophrenia under any genetic model in the total population. Further subgroup analysis by ethnicity also demonstrated that only GSTM1 polymorphism showed weak association with increased the risk of schizophrenia. We should also note the importance of heterogeneity. Heterogeneity was found in some comparisons in our meta-analysis. To get a more full and accurate detail of the precious data, we used the random-effects model. The results were stable with the sensitivity analysis, which did not change the results of the meta-analysis. Some limitations remain in this meta-analysis and the results should be interpreted with caution. First, meta-analysis is a secondary and retrospective study type that is limited by the quality of primary studies. Second, we were unable to analyze gene-gene and gene-environment interactions. This study investigated the relationship between GSTM1, GSTT1, and GSTP1 polymorphisms and the development of schizophrenia. In conclusion, we found that GSTM1 polymorphism was associated with susceptibility to schizophrenia in only East Asian population. Further larger studies considering gene-gene and gene-environment interactions are required to provide more precise evidence of the association between GSTM1, GSTT1, and GSTP1 and the risk of schizophrenia.

3. Experimental Section

3.1. Search Strategy

Case and control studies were searched in PubMed, Google, Embase, and Korean databases (KISS, KMbase, and RISS) up to April 2015 without language restrictions. Relevant studies were identified using the terms: “glutathione-related enzyme” or “GSTM, or GSTT, or GSTP” and “polymorphism or polymorphisms” and “schizophrenia”. Only human studies were selected. Additional studies were identified by hand search of original or review articles. If data or data subsets were published in more than one article, only the publication with the largest sample size was included.

3.2. Inclusion Criteria

Studies were included if they met the following criteria: (1) they evaluated the association between the GSTM1, GSTT1, or GSTP1 polymorphisms and schizophrenia; (2) they used a case-control study design; (3) and they contained sufficient distribution of GSTM1, GSTT1, or GSTP1 polymorphism in the schizophrenia group and the control group for the estimation of an odds ratio (OR) with a 95% confidence interval (CI).

3.3. Data Extraction

The two investigators independently extracted data and formed an analysis. When they differed in their conclusions, they rechecked the data again and reached a consensus through discussion. Data extracted from the selected articles included the first author’s name, year of publication, country of origin, ethnicity of the study population, number of cases and controls, and the genotype frequency of GSTM1, GSTT1, or GSTP1 polymorphisms.

3.4. Statistical Analysis

Meta-analysis was performed using a comprehensive meta-analysis software program (Corporation, NJ, USA). The pooled p value, OR and 95% CI were used to investigate the association between risk of schizophrenia and GSTM1, GSTT1, or GSTP1 polymorphisms. Firstly, we calculated the heterogeneity of studies. A χ2-test-based Q statistic test and I2 test were applied. The random-effects DerSimonian and Laird method was adopted if the result of the Q test was p < 0.05 or I2 statistic was >50%, which indicated a statistically significant degree of heterogeneity between the studies. Otherwise, the fixed-effects Mantel-Haenszel method was adopted. Publication bias was evaluated by Egger’s regression. For meta-analysis of GSTM1 and GSTT1 polymorphisms, the pooled ORs, 95% CI, and p value were calculated using null type versus (vs.) present type. And combination of GSTM1 and GSTT1 polymorphisms were also analyzed in meta-analysis [15]. For GSTP1, the pooled ORs were calculated for codominant 1 model (Ile/Ile vs. Ile/Val), codominant 2 model (Ile/Ile vs. Val/Val), dominant model (Ile/Ile vs. Ile/Val + Val/Val), recessive model (Ile/Ile + Ile/Val vs. Val/Val) and allelic model (Ile vs. Val). Further subgroup analysis by ethnicity, the East Asian population only included Koreans and Japanese. The value of p < 0.05 was regarded to indicate statistical significance.

4. Conclusions

GSTM1 polymorphism was associated with susceptibility to schizophrenia in only East Asian population and GSTT1 and GSTP1 polymorphisms did not related to schizophrenia.
  28 in total

Review 1.  Characterization of the omega class of glutathione transferases.

Authors:  Astrid K Whitbread; Amir Masoumi; Natasha Tetlow; Erica Schmuck; Marjorie Coggan; Philip G Board
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 2.  Recent advances in defining the neuropathology of schizophrenia.

Authors:  S E Arnold; J Q Trojanowski
Journal:  Acta Neuropathol       Date:  1996-09       Impact factor: 17.088

Review 3.  Free radical pathology and antioxidant defense in schizophrenia: a review.

Authors:  S P Mahadik; S Mukherjee
Journal:  Schizophr Res       Date:  1996-03       Impact factor: 4.939

4.  Analysis of glutathione S-transferase genes polymorphisms and the risk of schizophrenia in a sample of Iranian population.

Authors:  Farah Lotfi Kashani; Dor Mohammad Kordi-Tamandani; Roya Sahranavard; Mohammad Hashemi; Farzaneh Kordi-Tamandani; Adam Torkamanzehi
Journal:  Neuron Glia Biol       Date:  2012-07-06

Review 5.  Metabolism and functions of glutathione in brain.

Authors:  R Dringen
Journal:  Prog Neurobiol       Date:  2000-12       Impact factor: 11.685

6.  Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene.

Authors:  X Hu; H Xia; S K Srivastava; A Pal; Y C Awasthi; P Zimniak; S V Singh
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

7.  Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population.

Authors:  Daisuke Matsuzawa; Kenji Hashimoto; Tasuku Hashimoto; Eiji Shimizu; Hiroyuki Watanabe; Yuko Fujita; Masaomi Iyo
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-01-05       Impact factor: 3.568

8.  Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population.

Authors:  Chi-Un Pae; Jung-Jin Kim; Soo-Jung Lee; Chang-Uk Lee; Chul Lee; In-Ho Paik; Ho-Ran Park; Soo Yang; Alessandro Serretti
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-05       Impact factor: 5.067

Review 9.  Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.

Authors:  H Raunio; K Husgafvel-Pursiainen; S Anttila; E Hietanen; A Hirvonen; O Pelkonen
Journal:  Gene       Date:  1995-06-14       Impact factor: 3.688

10.  Genetic polymorphism of glutathione S-transferase T1: a candidate genetic modifier of individual susceptibility to schizophrenia.

Authors:  Mostafa Saadat; Fatemeh Mobayen; Hassan Farrashbandi
Journal:  Psychiatry Res       Date:  2007-06-22       Impact factor: 3.222

View more
  9 in total

1.  Editor's Highlight: Glutathione S-Transferase Activity Moderates Methylmercury Toxicity During Development in Drosophila.

Authors:  Daria Vorojeikina; Karin Broberg; Tanzy M Love; Philip W Davidson; Edwin van Wijngaarden; Matthew D Rand
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

2.  No association between GSTM1 and GSTT1 genetic polymorphisms and susceptibility to opium sap dependence.

Authors:  Khyber Saify; Mohammad Rashid Khalighinasab; Mostafa Saadat
Journal:  Mol Biol Res Commun       Date:  2016-03

3.  Glutathione S-transferases promote proinflammatory astrocyte-microglia communication during brain inflammation.

Authors:  Shin-Ichi Kano; Eric Y Choi; Eisuke Dohi; Swati Agarwal; Daniel J Chang; Ashley M Wilson; Brian D Lo; Indigo V L Rose; Santiago Gonzalez; Takashi Imai; Akira Sawa
Journal:  Sci Signal       Date:  2019-02-19       Impact factor: 8.192

4.  Links of platelet glutamate and glutathione metabolism with attenuated positive and negative symptoms in depressed patients at clinical high risk for psychosis.

Authors:  Irina S Boksha; Maria A Omel'chenko; Olga K Savushkina; Tatyana A Prokhorova; Elena B Tereshkina; Elena A Vorobyeva; Gulnur Sh Burbaeva
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-03-15       Impact factor: 5.270

5.  Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms.

Authors:  Bensu Karahalil; Aylin Elkama; Mehmet Ak; Emirhan Nemutlu
Journal:  Toxicol Res (Camb)       Date:  2022-06-01       Impact factor: 2.680

6.  GSTT1 and GSTM1 polymorphisms with human papillomavirus infection in women from southern Brazil: a case-control study.

Authors:  Ana Paula Reolon Bortolli; Valquíria Kulig Vieira; Indianara Carlotto Treco; Claudicéia Risso Pascotto; Guilherme Welter Wendt; Léia Carolina Lucio
Journal:  Mol Biol Rep       Date:  2022-05-04       Impact factor: 2.742

7.  Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility.

Authors:  Cinzia Ciccacci; Andrea Latini; Cristina Politi; Sandro Mancinelli; Maria C Marazzi; Giuseppe Novelli; Leonardo Palombi; Paola Borgiani
Journal:  Eur J Clin Pharmacol       Date:  2017-07-08       Impact factor: 3.064

8.  GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients.

Authors:  Denise S Pinheiro; Rodrigo da S Santos; Rodrigo B de Brito; Aline Helena da S Cruz; Paulo C Ghedini; Angela A S Reis
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

9.  Association Between Glutathione S-Transferase (GST) Polymorphisms and Schizophrenia in a Chinese Han Population.

Authors:  Ci Yan; Li Duan; Chunfeng Fu; Chunsheng Tian; Bihui Zhang; Xiaojun Shao; Gang Zhu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-18       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.